company background image
6696 logo

Lin BioScience TPEX:6696 Stock Report

Last Price

NT$100.50

Market Cap

NT$7.9b

7D

0.5%

1Y

-45.5%

Updated

23 Mar, 2024

Data

Company Financials

6696 Stock Overview

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases.

6696 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Lin BioScience, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lin BioScience
Historical stock prices
Current Share PriceNT$100.50
52 Week HighNT$205.00
52 Week LowNT$99.60
Beta0.0044
1 Month Change-11.06%
3 Month Change-14.47%
1 Year Change-45.53%
3 Year Change-36.39%
5 Year Change164.47%
Change since IPO105.06%

Recent News & Updates

We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely

Recent updates

We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely

We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely

Dec 10
We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely

Shareholder Returns

6696TW BiotechsTW Market
7D0.5%0.4%2.7%
1Y-45.5%-22.1%25.7%

Return vs Industry: 6696 underperformed the TW Biotechs industry which returned -22.1% over the past year.

Return vs Market: 6696 underperformed the TW Market which returned 25.8% over the past year.

Price Volatility

Is 6696's price volatile compared to industry and market?
6696 volatility
6696 Average Weekly Movement4.0%
Biotechs Industry Average Movement4.1%
Market Average Movement4.2%
10% most volatile stocks in TW Market8.0%
10% least volatile stocks in TW Market1.9%

Stable Share Price: 6696 has not had significant price volatility in the past 3 months.

Volatility Over Time: 6696's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/an/ahttps://www.linbioscience.com

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.

Lin BioScience, Inc. Fundamentals Summary

How do Lin BioScience's earnings and revenue compare to its market cap?
6696 fundamental statistics
Market capNT$7.89b
Earnings (TTM)-NT$518.43m
Revenue (TTM)n/a

0.0x

P/S Ratio

-15.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6696 income statement (TTM)
RevenueNT$0
Cost of RevenueNT$0
Gross ProfitNT$0
Other ExpensesNT$518.43m
Earnings-NT$518.43m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-6.61
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 6696 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.